In this article we are going to use hedge fund sentiment as a tool and determine whether ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a good investment right now.
Keep Reading →
December 14 - Hedge Funds, News - Comments
If you are looking for the best ideas for your portfolio you may want to consider some of Miller Value Partners top stock picks.
Keep Reading →
September 7 - Hedge Fund Investor Letters, News - Comments
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Keep Reading →
June 30 - Hedge Funds, News - Comments
Is ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Keep Reading →
December 11 - Hedge Funds, News - Comments
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons.
Keep Reading →
October 28 - Hedge Funds, News - Comments
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics ...
Keep Reading →
December 23 - Hedge Funds, News - Comments
In Donald Trump’s latest press conference, the President-elect took a swipe at the healthcare and pharmaceutical space, suggesting that drug companies are getting away with ...
Keep Reading →
January 12 - News, Stock Analysis - Comments
We have been waiting for this for a year and finally the third quarter ended up showing a nice bump in the performance of small-cap stocks.
Keep Reading →
December 18 - Hedge Funds, News - Comments
Insider Monkey keeps a keen eye on the activity of the top hedge funds in the world, as our research has shown that hedge funds’ long positions can deliver market-beating returns...
Keep Reading →
November 26 - Hedge Funds, News - Comments
All three indexes are now in the red as some traders take profit from the market's run-up since the Brexit, while others remain cautious given the state of the global economy.
Keep Reading →
July 19 - Earnings Report, Market Movers, News - Comments
The markets have struggled to extend their record-making gains achieved earlier this week as investors react to Thursday’s terrorist attack in Nice, France.
Keep Reading →
July 15 - Market Movers, News - Comments
With all three indexes in the green today, shares of Mobileye NV (NYSE:MBLY), Fitbit Inc (NYSE:FIT), Gladstone Capital Corporation (NASDAQ:GLAD), and ZIOPHARM Oncology Inc.
Keep Reading →
January 14 - Market Movers, News - Comments
We can judge whether ZIOPHARM Oncology Inc.
Keep Reading →
December 11 - Hedge Funds, News - Comments
The U.S stock market seems to be heading for a second day of losses, as the morning rally has not lasted.
Keep Reading →
October 14 - Market Movers, News - Comments
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), Intrexon Corp (NYSE:XON), and Heron Therapeutics Inc (NASDAQ:HRTX) are down significantly today amid a broader market decline.
Keep Reading →
September 28 - Market Movers, News - Comments
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
September 17 - News - Comments
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Keep Reading →
September 17 - News - Comments
To the average investor, there are tons of metrics shareholders can use to analyze Mr. Market. A duo of the best are hedge fund and insider trading interest.
Keep Reading →
September 15 - News - Comments
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
Keep Reading →
September 6 - News - Comments
In the eyes of most stock holders, hedge funds are seen as underperforming, outdated financial vehicles of years past.
Keep Reading →
June 26 - News - Comments
Pacific Biosciences of California (NASDAQ:PACB) was in 7 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 19 - News - Comments
To most investors, hedge funds are assumed to be worthless, old investment tools of the past.
Keep Reading →
June 17 - News - Comments
Biotech stocks can provide astronomical returns but also depressing losses.
Keep Reading →
June 14 - News - Comments
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News - Comments
BioDelivery Sciences International, Inc.
Keep Reading →
June 13 - News - Comments
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Keep Reading →
June 10 - News - Comments
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was in 6 hedge funds' portfolio at the end of December.
Keep Reading →
April 19 - News - Comments
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Keep Reading →
April 13 - News - Comments
With the SPDR S&P Biotech (ETF) (NYSEARCA:XBI) Index up 25% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector...
Keep Reading →
March 31 - News - Comments
Have you checked your 401(k) or IRA balance lately? If you're like many people, the numbers brought forth a smile, with the major indexes hitting record highs.
Keep Reading →
March 30 - News - Comments
Biotechs offer the possibility of monster returns. Overnight doubles aren't out of the question.
Keep Reading →
March 28 - News - Comments
Cancer just might be one of the scariest words in the English language. What goes through your mind when you hear that someone close to you has cancer? Sadness, probably.
Keep Reading →
March 11 - News - Comments
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
February 18 - News - Comments
Sweet! No, I'm not talking about leftover Valentine's Day candy and chocolates. Sweet is the operative word for the returns attained by several health-care stocks this week.
Keep Reading →
February 16 - News - Comments
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.
Keep Reading →
February 2 - News - Comments